Bluebird faces setback on gene therapy development, while Vertex renews focus on CRISPR technology The realm of gene editing has witnessed significant progress and an ever-changing landscape in recent years, with a multitude of biotech companies and esteemed academic institutions heavily investing in extensive research and development of novel therapies for a gamut of genetic disorders. The advent of gene editing technologies, particularly CRISPR-Cas9, has opened up unprecedented possibilities for treating and curing genetic ailments by meticulously targeting and modifying specific genes in the patient's DNA. #geneeditingmarketsize #asiapacificcelltherapymarketresearch #europeprecisionmedicinemarketreport #biotechnologymarketresearchreport #globalbiotechnologyresearchreport #europegeneeditingmarketreport